FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286511207> ?p ?o ?g. }

• W4286511207 endingPage "730" @default.
• W4286511207 startingPage "720" @default.
• W4286511207 abstract "Brigatinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor with demonstrated efficacy in locally advanced and metastatic non-small cell lung cancer (NSCLC) in crizotinib-refractory and ALK inhibitor-naive settings. This analysis assessed brigatinib in Asian vs. non-Asian patients from the first-line ALTA-1L trial.This was a subgroup analysis from the phase III ALTA-1L trial of brigatinib vs. crizotinib in ALK inhibitor-naive ALK+ NSCLC. The primary endpoint was progression-free survival (PFS) as assessed by blinded independent review committee (BIRC). Secondary endpoints included confirmed objective response rate (ORR) and overall survival (OS) in the overall population and BIRC-assessed intracranial ORR and PFS in patients with brain metastases.Of the 275 randomized patients, 108 were Asian. Brigatinib showed consistent superiority in BIRC-assessed PFS vs. crizotinib in Asian (hazard ratio [HR]: 0.35 [95% CI: 0.20-0.59]; log-rank P = .0001; median 24.0 vs. 11.1 months) and non-Asian (HR: 0.56 [95% CI: 0.38-0.84]; log-rank P = .0041; median 24.7 vs. 9.4 months) patients. Results were consistent with investigator-assessed PFS and BIRC-assessed intracranial PFS. Brigatinib was well tolerated. Toxicity profiles and dose modification rates were similar between Asian and non-Asian patients.Efficacy with brigatinib was consistently better than with crizotinib in Asian and non-Asian patients with locally advanced or metastatic ALK inhibitor-naive ALK-+ NSCLC. There were no clinically notable differences in overall safety in Asian vs. non-Asian patients." @default.
• W4286511207 created "2022-07-22" @default.
• W4286511207 creator A5005127397 @default.
• W4286511207 creator A5008594172 @default.
• W4286511207 creator A5011220643 @default.
• W4286511207 creator A5012226414 @default.
• W4286511207 creator A5022432835 @default.
• W4286511207 creator A5025910383 @default.
• W4286511207 creator A5043485695 @default.
• W4286511207 creator A5044613951 @default.
• W4286511207 creator A5045384053 @default.
• W4286511207 creator A5046993997 @default.
• W4286511207 creator A5048231332 @default.
• W4286511207 creator A5052962511 @default.
• W4286511207 creator A5057051442 @default.
• W4286511207 creator A5062159183 @default.
• W4286511207 creator A5064222874 @default.
• W4286511207 creator A5073896274 @default.
• W4286511207 creator A5078507307 @default.
• W4286511207 creator A5079966483 @default.
• W4286511207 creator A5082517668 @default.
• W4286511207 creator A5087860798 @default.
• W4286511207 creator A5090324173 @default.
• W4286511207 date "2022-12-01" @default.
• W4286511207 modified "2023-10-18" @default.
• W4286511207 title "Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK–Inhibitor-Naive ALK+ Non–Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study" @default.
• W4286511207 cites W2019607817 @default.
• W4286511207 cites W2031494655 @default.
• W4286511207 cites W2050249255 @default.
• W4286511207 cites W2099530756 @default.
• W4286511207 cites W2168106545 @default.
• W4286511207 cites W2170144893 @default.
• W4286511207 cites W2172010139 @default.
• W4286511207 cites W2345320779 @default.
• W4286511207 cites W2551769647 @default.
• W4286511207 cites W2581996620 @default.
• W4286511207 cites W2624310346 @default.
• W4286511207 cites W2766602847 @default.
• W4286511207 cites W2769618607 @default.
• W4286511207 cites W2803802743 @default.
• W4286511207 cites W2887380463 @default.
• W4286511207 cites W2894476389 @default.
• W4286511207 cites W2939690516 @default.
• W4286511207 cites W2947037568 @default.
• W4286511207 cites W2991627091 @default.
• W4286511207 cites W3022131485 @default.
• W4286511207 cites W3048441995 @default.
• W4286511207 cites W3101089668 @default.
• W4286511207 cites W3200994971 @default.
• W4286511207 cites W4206436013 @default.
• W4286511207 doi "https://doi.org/10.1016/j.cllc.2022.07.008" @default.
• W4286511207 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36038416" @default.
• W4286511207 hasPublicationYear "2022" @default.
• W4286511207 type Work @default.
• W4286511207 citedByCount "2" @default.
• W4286511207 countsByYear W42865112072022 @default.
• W4286511207 countsByYear W42865112072023 @default.
• W4286511207 crossrefType "journal-article" @default.
• W4286511207 hasAuthorship W4286511207A5005127397 @default.
• W4286511207 hasAuthorship W4286511207A5008594172 @default.
• W4286511207 hasAuthorship W4286511207A5011220643 @default.
• W4286511207 hasAuthorship W4286511207A5012226414 @default.
• W4286511207 hasAuthorship W4286511207A5022432835 @default.
• W4286511207 hasAuthorship W4286511207A5025910383 @default.
• W4286511207 hasAuthorship W4286511207A5043485695 @default.
• W4286511207 hasAuthorship W4286511207A5044613951 @default.
• W4286511207 hasAuthorship W4286511207A5045384053 @default.
• W4286511207 hasAuthorship W4286511207A5046993997 @default.
• W4286511207 hasAuthorship W4286511207A5048231332 @default.
• W4286511207 hasAuthorship W4286511207A5052962511 @default.
• W4286511207 hasAuthorship W4286511207A5057051442 @default.
• W4286511207 hasAuthorship W4286511207A5062159183 @default.
• W4286511207 hasAuthorship W4286511207A5064222874 @default.
• W4286511207 hasAuthorship W4286511207A5073896274 @default.
• W4286511207 hasAuthorship W4286511207A5078507307 @default.
• W4286511207 hasAuthorship W4286511207A5079966483 @default.
• W4286511207 hasAuthorship W4286511207A5082517668 @default.
• W4286511207 hasAuthorship W4286511207A5087860798 @default.
• W4286511207 hasAuthorship W4286511207A5090324173 @default.
• W4286511207 hasBestOaLocation W42865112071 @default.
• W4286511207 hasConcept C117643217 @default.
• W4286511207 hasConcept C126322002 @default.
• W4286511207 hasConcept C143998085 @default.
• W4286511207 hasConcept C203092338 @default.
• W4286511207 hasConcept C207103383 @default.
• W4286511207 hasConcept C2776232967 @default.
• W4286511207 hasConcept C2776256026 @default.
• W4286511207 hasConcept C2776694085 @default.
• W4286511207 hasConcept C2778347629 @default.
• W4286511207 hasConcept C2779422266 @default.
• W4286511207 hasConcept C2780739268 @default.
• W4286511207 hasConcept C44249647 @default.
• W4286511207 hasConcept C535046627 @default.
• W4286511207 hasConcept C71924100 @default.
• W4286511207 hasConceptScore W4286511207C117643217 @default.
• W4286511207 hasConceptScore W4286511207C126322002 @default.
• W4286511207 hasConceptScore W4286511207C143998085 @default.
• W4286511207 hasConceptScore W4286511207C203092338 @default.

• next